Variation in the genes encoding vesicular monoamine transporter 2 and beta-1 adrenergic receptor and antidepressant treatment outcome

Psychiatric Genetics

Volumn 18, Issue 5, 2008, Pages 248-251

  Crowley, James J ^a   Lipsky, Robert H ^b   Lucki, Irwin ^a   Berrettini, Wade H ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

ADRB1; Antidepressant; Depression; Pharmacogenetic; Sequenced treatment alternatives to relieve depression; SLC18A2

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; CITALOPRAM; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MONOAMINE METABOLISM; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ALLELES; ANTIDEPRESSIVE AGENTS; DEPRESSION; GENE FREQUENCY; HUMANS; LINKAGE DISEQUILIBRIUM; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ADRENERGIC, BETA-1; TREATMENT OUTCOME; VARIATION (GENETICS); VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 55049103994     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/YPG.0b013e3283052ff7     Document Type: Article

References (8)

1. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA (2004). Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106-120.
2. Crowley JJ, Brodkin ES, Blendy JA, Berrettini WH, Lucki I (2006). Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology 31:2433-2442.
3. Gauderman WJ, Morrison JM (2006). QUANTO 1.1: A computer program for power and sample size calculations for genetic-epidemiology studies, http://hydra.usc.edu/gxe
4. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP (2007). Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 61:734-742.
5. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, et al. (2006). Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 78:804-814.
6. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. (2004). Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119-142.
7. Sandilands AJ, O'Shaughnessy KM (2005). The functional significance of genetic variation within the beta-adrenoceptor. Br J Clin Pharmacol. 60: 235-243.
8. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al.; STAR*D Study Team (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28-40.